The 2025 Nature paper is genuinely important: it reported that lithium replacement using lithium orotate, a salt with reduced amyloid binding, prevented pathological changes and memory loss in Alzheimer's mouse models and in ageing wild-type mice. Those were mouse experiments. The human evidence at supplement doses amounts to brain-imaging pharmacokinetics, observational data, and one small open trial — no randomized trial has tested 5 mg lithium orotate for cognition, mood or aging. The randomized human lithium data that do exist used psychiatric-adjacent doses, roughly 25 to 40 times what a capsule contains.
Lithium orotate is a salt of the trace element lithium and orotic acid, sold as a low-dose dietary supplement that typically provides only a few milligrams of elemental lithium per serving—far below the doses of lithium carbonate (roughly 150-1,200 mg) used as a prescription mood stabilizer. Lithium occurs naturally in drinking water, grains and vegetables and is ingested in variable trace amounts through the diet. At the cellular level, lithium inhibits the enzymes glycogen synthase kinase-3β (GSK-3β) and inositol monophosphatase, actions linked to increased neurotrophic signaling, autophagy and reduced phosphorylation of tau protein.
Claims below are supported by the primary sources linked under each line — the same sources we cite on the product page.
Each line pairs a claim that circulates in marketing and forums with the trial result that contradicts or narrows it.
Quotations are verbatim from the cited paper. Negative and inconclusive trials are listed alongside the positive ones because that is the whole point of this page.
“Replacement therapy with lithium orotate, which is a Li salt with reduced amyloid binding, prevents pathological changes and memory loss in AD mouse models and ageing wild-type mice.”
“Low-dose lithium was not efficacious in treating agitation but was associated with global clinical improvement and excellent safety.”
“Long-term increased lithium exposure in drinking water may be associated with a lower incidence of dementia in a nonlinear way; however, confounding from other factors associated with municipality of residence cannot be excluded.”
“We find an inverse correlation between drinking water lithium concentrations and all-cause mortality in 18 neighbouring Japanese municipalities (1,206,174 individuals)... a comparably low concentration of lithium extends lifespan of C. elegans.”
Result: In humans, an inverse correlation was found between drinking water lithium concentrations and all-cause mortality in 18 Japanese municipalities, involving 1,206,174 individuals. Exposure to a comparably low concentration of lithium chloride extended the lifespan of C. elegans.
“Participants in the placebo group displayed cognitive and functional decline, whereas lithium-treated patients remained stable over 2 years.”
The most firmly established human benefit of lithium is a reduction in suicide and all-cause mortality among people with mood disorders, demonstrated in meta-analyses of randomized trials, while small trials and their meta-analyses suggest that subtherapeutic or 'microdose' lithium may slow cognitive decline in mild cognitive impairment and Alzheimer's disease. Ecological and cohort studies link higher natural lithium in drinking water to lower rates of dementia and suicide, and low-dose lithium extends lifespan in model organisms, but these findings are inconsistent—some null, nonlinear or potentially confounded. Imaging studies confirm that supplement-level lithium doses measurably reach the human brain, and a landmark 2025 study found brain lithium reduced in mild cognitive impairment and showed lithium orotate reversing Alzheimer's-like pathology—but its interventional arm was in mice, not a clinical trial, and experts caution against self-treating before human trials are done. Whether the orotate salt is meaningfully different from other lithium forms is still debated, high-dose lithium carries real toxicity, and no randomized trial has tested 5 mg lithium orotate for cognition, mood or aging. This evidence describes the element lithium and its mechanisms generally, not this specific commercial lithium orotate product.
A grade that cannot be falsified is a marketing claim. These are the specific results that would move this one up.
We are not recommending this one. The mouse paper is excellent science and the reasonable response to excellent mouse science is to fund the human trial, not to start dosing. If you already take lithium for a psychiatric indication, this is a conversation for your prescriber and not a supplement decision. If your interest is brain health, the interventions with human outcome evidence are blood-pressure control, hearing correction, exercise and sleep — and the first of those is measurable at home for under a hundred dollars.
We are not putting a buy button on this page. The product page stays up, with the same grade and the same reasoning, so you can see exactly what we think of it: Lithium Orotate (5 mg) — graded Emerging evidence →
Graded Strong. Midlife blood pressure control has the strongest outcome evidence of anything in the brain-health conversation.
Graded Strong for muscle, with a promising and openly-labelled-as-less-settled cognitive literature.
Graded Strong. Circadian timing is a lever with real trial evidence behind it.
Where the brain-intervention field actually stands, implants and ultrasound included.
Low-dose lithium molecule page · BDNF · Lithium orotate — the graded product page · The drinking-water lithium and longevity study, in full · Nutraceuticals and cellular energizers · The full evidence record
Sibling pages in this record: NMN (nicotinamide mononucleotide) · Resveratrol · Vitamin D · Omega-3 fish oil
It reported that lithium deficiency was associated with Alzheimer's pathology, and that replacement therapy with lithium orotate — chosen because it binds amyloid less than other lithium salts — prevented pathological changes and memory loss. In mouse models and ageing wild-type mice. It is a genuinely important paper about disease biology, and it is not a human trial.
Nobody has run the study that would answer that properly. Lithium has a narrow therapeutic index at psychiatric doses, and long-term safety data at supplement doses are incomplete — that is the honest state of the record, and it is what our grade note says. This is a question for a clinician, particularly if you have thyroid or kidney disease or take medications that affect lithium levels.
Some were, and they are good trials — over two years, lithium-treated patients remained stable while placebo participants declined. They used doses far above 5 mg of elemental lithium. Applying a result from a 25-to-40-fold higher dose to a capsule is not a conservative extrapolation, it is the central error this page is about.
Because people search for it and will buy it somewhere. A listing with an Emerging grade, a grade note stating that experts caution against self-treatment pending human trials, and a page like this one is more useful than pretending the product does not exist. There is no purchase link on this page.